215 related articles for article (PubMed ID: 28317392)
21. The efficacy of vortioxetine for the treatment of major depressive disorder.
Dhir A; Sarvaiya J
Expert Rev Neurother; 2014 Dec; 14(12):1349-63. PubMed ID: 25418918
[TBL] [Abstract][Full Text] [Related]
22. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials.
McIntyre RS; Muzina DJ; Adams A; Lourenco MT; Law CW; Soczynska JK; Woldeyohannes HO; Nathanson J; Kennedy SH
Expert Opin Pharmacother; 2009 Dec; 10(18):3061-75. PubMed ID: 19954275
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.
Bundgaard C; Eneberg E; Sánchez C
Neuropharmacology; 2016 Apr; 103():104-11. PubMed ID: 26700248
[TBL] [Abstract][Full Text] [Related]
24. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
25. Vortioxetine for the treatment of depression.
Pearce EF; Murphy JA
Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
[TBL] [Abstract][Full Text] [Related]
27. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
[TBL] [Abstract][Full Text] [Related]
28. An update on antidepressant pharmacotherapy in late-life depression.
Brender R; Mulsant BH; Blumberger DM
Expert Opin Pharmacother; 2021 Oct; 22(14):1909-1917. PubMed ID: 33910422
[No Abstract] [Full Text] [Related]
29. An overview of vortioxetine.
Schatzberg AF; Blier P; Culpepper L; Jain R; Papakostas GI; Thase ME
J Clin Psychiatry; 2014 Dec; 75(12):1411-8. PubMed ID: 25551236
[TBL] [Abstract][Full Text] [Related]
30. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Vellante F; Fornaro M; Fiengo A; Mazza M; Vecchiotti R; Perna G; de Bartolomeis A; Martinotti G; Di Giannantonio M; De Berardis D
Expert Rev Neurother; 2016 May; 16(5):483-95. PubMed ID: 27050932
[TBL] [Abstract][Full Text] [Related]
31. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of augmentation strategies for patients with major depressive disorder.
Fleurence R; Williamson R; Jing Y; Kim E; Tran QV; Pikalov AS; Thase ME
Psychopharmacol Bull; 2009; 42(3):57-90. PubMed ID: 19752841
[TBL] [Abstract][Full Text] [Related]
33. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.
Smagula SF; Wallace ML; Anderson SJ; Karp JF; Lenze EJ; Mulsant BH; Butters MA; Blumberger DM; Diniz BS; Lotrich FE; Dew MA; Reynolds CF
J Psychiatr Res; 2016 Oct; 81():112-8. PubMed ID: 27438687
[TBL] [Abstract][Full Text] [Related]
34. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
Clayton AH; Kennedy SH; Edwards JB; Gallipoli S; Reed CR
J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
[TBL] [Abstract][Full Text] [Related]
35. [Vortioxetine: a new antidepressant to treat depressive episodes].
Colle R; Corruble E
Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
[TBL] [Abstract][Full Text] [Related]
36. Drugs for Depression.
Med Lett Drugs Ther; 2020 Feb; 62(1592):25-32. PubMed ID: 32320387
[No Abstract] [Full Text] [Related]
37. Vilazodone: a review in major depressive disorder in adults.
McCormack PL
Drugs; 2015 Nov; 75(16):1915-23. PubMed ID: 26496736
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
Cruz N; Sanchez-Moreno J; Torres F; Goikolea JM; Valentí M; Vieta E
Int J Neuropsychopharmacol; 2010 Feb; 13(1):5-14. PubMed ID: 19638254
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
McIntyre RS; Gommoll C; Chen C; Ruth A
CNS Spectr; 2016 Oct; 21(5):385-392. PubMed ID: 27292817
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic potential of new second generation antipsychotics for major depressive disorder.
McElroy SL; Guerdjikova A; Mori N; Keck PE
Expert Opin Investig Drugs; 2010 Dec; 19(12):1527-44. PubMed ID: 21105856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
